^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-07263689

    i
    Other names: PF-07263689
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=13, Terminated, Pfizer | N=10 --> 13 | Active, not recruiting --> Terminated; The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    IL2 (Interleukin 2)
    |
    sasanlimab (PF-06801591) • PF-07263689
    2years
    Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=120 --> 10 | Trial completion date: Apr 2025 --> Dec 2022 | Trial primary completion date: Apr 2025 --> Dec 2022
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    IL2 (Interleukin 2)
    |
    sasanlimab (PF-06801591) • PF-07263689
    over2years
    Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=120, Recruiting, Pfizer | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    sasanlimab (PF-06801591) • PF-07263689
    3years
    Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=120, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    sasanlimab (PF-06801591) • PF-07263689
    3years
    Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Pfizer
    Clinical • New P1 trial • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    sasanlimab (PF-06801591) • PF-07263689